Immunogenicity and safety of BNT162b2 mRNA vaccine in outpatients on dialysis: Double center prospective observational study in Japa
Not Applicable
- Conditions
- dialysis patients
- Registration Number
- JPRN-UMIN000044500
- Lead Sponsor
- Shonan Fujisiawa Tokushukai Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Not provided
Exclusion Criteria
aged <16 years being infected SARS-CoV-2 and in isolation having already received the vaccine not wishing to be vaccinated by their own choice or on the recommendation of their physician; and did not provide informed consent.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Antibody titer of anti-spike protein IgG before first vaccination, at the time of the second vaccination, and 14 days after the second vaccination, 90 days, and 180 days after vaccination
- Secondary Outcome Measures
Name Time Method